Skip to main content

Table 1 Anatomical and functional measurement of all subjects

From: Microperimetry and OCT angiography evaluation of patients with ischemic diabetic macular edema treated with monthly intravitreal bevacizumab: a pilot study

 

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

BCVA baseline

20/400

20/200

20/100

20/100

20/100

BCVA 6 months

20/100

20/80

20/100

20/50

20/40

Macular sensitivity baseline (dB)

11.3

11.7

12.8

10.7

11.8

Macular sensitivity 6 months (dB)

15.2

21.8

16.4

14.6

13.3

OCT foveal thickness baseline (um)

474

722

423

321

449

OCT foveal thickness 6 months (um)

371

275

393

215

453

FAZ measure—FA baseline (mm2)

0.22

3.77

0.32

0.98

1.47

FAZ measure—FA 6 months (mm2)

0.12

2.08

0.41

0.99

1.54

FAZ measure—OCTA baseline (mm2)

0.23

NA

NA

0.89

1.33

FAZ measure—OCTA 6 months (mm2)

0.25

NA

NA

1.03

1.42

  1. BCVA best correct visaul acuity; OCT optical coherence tomography; FAZ foveal avascular zone; FA: fluorescein angiography; OCTA optical coherence tomography with angiography